1. Dean L. Pertuzumab therapy and ERBB2 (HER2) genotype drug. Pertuzumab. 2015;2:1–7.
2. Lenneman CG, Abdallah WM, Smith HM, Abramson V, Mayer IA, Silverstein C, et al. Sympathetic nervous system alterations with HER2+ antagonism: an early marker of cardiac dysfunction with breast cancer treatment? Ecancermedicalscience. 2014;8:446.
3. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523–9.
4. Amler L, Wang Y, Hampton G. HER2 as a Therapeutic target in ovarian cancer. Intechopen.Com [Internet]. 2010;10:1343–4.
5. Ferguson KM. A structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys [Internet]. 2008;37:353–73.